Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double‐blind trial
- 29 April 2010
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 106 (9), 1352-1356
- https://doi.org/10.1111/j.1464-410x.2010.09331.x
Abstract
To assess the role of extracorporeal shock wave therapy (SWT), in a prospective randomized controlled trial, comparing limited SWT vs sham therapy in men with Peyronie's disease. In all, 36 men were randomized to six sessions of SWT or sham treatment. Geometrical measurements of penile length and deformity, and the abridged International Index of Erectile Function (IIEF) score and visual analogue score (VAS) were recorded and re-evaluated at 6 months. The patient and assessor were unaware of the treatment type. Standard nonparametric tests were used for the statistical analysis. A full set of outcome data was obtained for 16 patients in the intervention group and 20 in the sham/control group (mean age 58 and 60 years, respectively, mean duration of symptoms 15 and 33 months). There was no significant difference in the mean change between the control and intervention groups on any outcome measure. There were improvements in the mean (sd) dorsal and lateral angle, of 5.3 (11.66)° and 3.5 (17.38)° in the control group, and a deterioration of 0.9 (16.01)° and 0.9 (15.56)° in SWT group. Mean improvements in curved and straight lengths were 0.2 (0.58) and 0.1 (0.8) cm in the control and mean reductions of 0.1 (0.9) and 0.1 (1.49) cm in the SWT group. The mean changes in the IIEF and VAS scores were 0.1 (3.32) and -0.8 (1.77) for control and 0.56 (2.6) and -1.05 (1.79) for SWT group. There were no significant differences in changes of variables in Peyronie's disease treated with short-term SWT.Keywords
This publication has 18 references indexed in Scilit:
- Investigation of the Antifibrotic Effect of IFN-γ on Fibroblasts in a Cell Culture Model of Peyronie's DiseaseEuropean Urology, 2008
- Extracorporeal Shockwave Therapy for Peyronie's Disease: Who Benefits?Journal of Endourology, 2006
- An alternative non-invasive treatment for Peyronie's diseaseInternational braz j urol, 2004
- Evaluation of extracorporeal shock wave therapy in Peyronie’s diseaseUrology, 2002
- Epidemiology of Peyronie's diseaseInternational Journal Of Impotence Research, 2002
- Extracorporeal shock wave treatment for Peyronie’s disease using EDAP LT‐02; preliminary resultsInternational Journal of Urology, 2002
- Extrakorporale Stoßwellentherapie (ESWT)in Kombination mit lokalen Verapamil-Injektionen zur Therapie der IPP (Induratio penis plastica)Aktuelle Urologie, 2001
- PEYRONIE'S DISEASEUrologic Clinics of North America, 2001
- Extracorporal Shock Wave Therapy in the Treatment of Peyronie’s DiseaseEuropean Urology, 2000
- Treatment of Peyronie's Disease by Extracorporeal Shockwave Therapy: Evaluation of Our Preliminary ResultsJournal of Endourology, 1999